IPO
Coverage Timeline
newest firstAll Coverage
IPO~$67.8M net
Vogenx Prices $68M IPO for Metabolic Drug
Vogenx priced 6.25M shares at $12 to raise roughly $68M net, funding development of mizagliflozin, an SGLT1 inhibitor for gastrointestinal and metabolic disorders, through 2028.
IPO
Jaguar Health, Vogenx Join a Growing Biotech S-1 Queue
IPO
Jaguar Health, Vogenx Join a Growing Biotech S-1 Queue
Jaguar Health and Vogenx both filed S-1 paperwork with the SEC, adding to a biotech IPO queue that's grown steadily through 2026 as public-market appetite for clinical-stage listings recovers.